Prolonged overall survival in gastric cancer patients after adoptive immunotherapy

Table 5 Subgroup analysis

Subgroup	Median OS (mo)		RR (95%CI)	P value
	Immunotherapy group	Control group
Age (yr)
< 60	25.8	13.4	0.65 (0.333-1.272)	0.209
≥ 60	46.5	13.9	0.502 (0.233-1.079)	0.078
Gender
Male	20.0	15.0	0.439 (0.146-1.32)	0.143
Female	30.5	13.9	0.625 (0.355-1.099)	0.103
Clinical stage
I and II	60.0	62.2	1.212 (0.293-5.013)	0.791
IIIa and IIIb	49.3	28.4	0.358 (0.128-1.003)	0.051
IIIc and IV	14.0	10.0	0.484 (0.251-0.933)	0.03a
Surgery
Yes	36.0	15.4	0.561 (0.319-0.986)	0.045a
No	19.7	9.4	0.265 (0.069-1.015)	0.053
Radiotherapy
Yes	60.0	43.5	0.382 (0.094-1.55)	0.178
No	22.0	13.4	0.624 (0.364-1.069)	0.086
Chemotherapy cycles
≤ 6 cycles	27.0	10.0	0.544 (0.255-1.159)	0.115
> 6 cycles	30.5	18.4	0.554 (0.28-1.093)	0.089

^aP < 0.05 was considered statistically significant.